Free tool
FAERS Monitor: Vivjoa
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 215888 or its brand name (Vivjoa, Oteseconazole). Reports on generic versions are filed under their own applications.
Reports
43
Serious
3
7% of reports
Hospitalization
0
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective8
- fungal infection5
- dysuria4
- inappropriate schedule of product administration4
- off label use4
- vulvovaginal pruritus4
- dizziness3
- nausea3
- candida infection2
- diarrhoea2
- erythema2
- headache2
- hot flush2
- insomnia2
- pain2
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2023 | 14 |
| 2024 | 9 |
| 2025 | 4 |
| 2026 | 16 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,116 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| vulvovaginal pruritusSignal | 4 | 386.6 | 152.0 | 1,176 |
| fungal infectionSignal | 5 | 73.4 | 32.2 | 289 |
| candida infection | 2 | 57.9 | 15.0 | 62 |
| dysuriaSignal | 4 | 53.2 | 20.9 | 156 |
| hot flush | 2 | 13.0 | 3.4 | 12 |
| inappropriate schedule of product administrationSignal | 4 | 10.9 | 4.3 | 27 |
| erythema | 2 | 4.8 | 1.2 | 3 |
| insomnia | 2 | 3.7 | 0.9 | 2 |
| drug ineffectiveSignal | 8 | 3.0 | 1.6 | 9 |
| dizziness | 3 | 2.9 | 1.0 | 2 |
| off label use | 4 | 2.2 | 0.9 | 2 |
| nausea | 3 | 1.9 | 0.6 | 0 |
| pain | 2 | 1.6 | 0.4 | 0 |
| headache | 2 | 1.6 | 0.4 | 0 |
| diarrhoea | 2 | 1.5 | 0.4 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.